2009
Developing A Policy For Second-Generation Antipsychotic Drugs
Rosenheck RA, Sernyak MJ. Developing A Policy For Second-Generation Antipsychotic Drugs. Health Affairs 2009, 28: w782-w793. PMID: 19622538, DOI: 10.1377/hlthaff.28.5.w782.Peer-Reviewed Original ResearchConceptsSecond-generation antipsychoticsAntipsychotic drugsRisk/benefit profileSecond-generation antipsychotic drugsMetabolic side effectsTreatment of schizophreniaAdverse eventsBenefit profileLower riskOld drugsSide effectsPrior authorizationDrugsCheaper drugsGeneric drugsEducational preparationWidespread implementationGood acceptanceSuch proceduresAntipsychoticsPatientsTherapySchizophrenia
2006
Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic
Stroup T, Lieberman J, McEvoy J, Swartz M, Davis S, Rosenheck R, Perkins D, Keefe R, Davis C, Severe J, Hsiao J. Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. FOCUS The Journal Of Lifelong Learning In Psychiatry 2006, 4: 539-552. DOI: 10.1176/foc.4.4.539.Peer-Reviewed Original ResearchAtypical antipsychoticsChronic schizophreniaDouble-blind treatmentDouble-blind studyGroup of patientsDifferent atypical antipsychoticsEffectiveness of olanzapineTreatment of schizophreniaClinical Antipsychotic TrialsTreatment discontinuationPrevious antipsychoticDifferent antipsychoticsAntipsychotic TrialsAntipsychoticsQuetiapineDiscontinuationPatientsOlanzapineRisperidoneZiprasidonePrevious treatmentSchizophreniaTreatmentSignificant differencesPrimary aim
2001
Use of Pharmacy Data to Assess Quality of Pharmacotherapy for Schizophrenia in a National Health Care System
Leslie D, Rosenheck R. Use of Pharmacy Data to Assess Quality of Pharmacotherapy for Schizophrenia in a National Health Care System. Medical Care 2001, 39: 923-933. PMID: 11502950, DOI: 10.1097/00005650-200109000-00003.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAdultAntipsychotic AgentsComorbidityDelivery of Health Care, IntegratedDiagnosis, Dual (Psychiatry)FemaleGuideline AdherenceHumansMaleMental Health ServicesMiddle AgedNational Health ProgramsOutcome and Process Assessment, Health CarePatient CompliancePolypharmacyPractice Guidelines as TopicSchizophreniaUnited StatesUnited States Department of Veterans AffairsConceptsPatient Outcomes Research TeamLarger mental health systemMultiple antipsychotic medicationsAntipsychotic medicationPORT recommendationsSchizophrenia Patient Outcomes Research TeamVeterans AffairsHealth systemTotal weekly doseTreatment of schizophreniaPrescription drug recordsMental health systemHealth care systemGeneralized estimation equationsMultiple antipsychoticsNational Health SystemOlder patientsWeekly doseNational health care systemPharmacy dataComorbid depressionTreatment recommendationsDrug recordsMedicationsPatientsThe Effect of Institutional Fiscal Stress on the Use of Atypical Antipsychotic Medications in the Treatment of Schizophrenia
LESLIE D, ROSENHECK R. The Effect of Institutional Fiscal Stress on the Use of Atypical Antipsychotic Medications in the Treatment of Schizophrenia. The Journal Of Nervous And Mental Disease 2001, 189: 377-383. PMID: 11434638, DOI: 10.1097/00005053-200106000-00005.Peer-Reviewed Original ResearchMeSH KeywordsAlzheimer DiseaseAntipsychotic AgentsBenzodiazepinesBudgetsClozapineComorbidityDepressive DisorderDrug CostsFemaleHealth Care CostsHealth FacilitiesHumansMaleMiddle AgedOlanzapinePirenzepinePractice Patterns, Physicians'Regression AnalysisRisperidoneSchizophreniaTreatment OutcomeUnited StatesUnited States Department of Veterans AffairsConceptsAtypical antipsychotic medicationsTreatment of schizophreniaAtypical antipsychoticsAntipsychotic medicationExpensive atypical antipsychotic medicationsVeterans AffairsPrescription drug recordsGeneralized estimation equationsDrug recordsPatientsReduced likelihoodAntipsychoticsMedicationsFacility characteristicsSchizophreniaAtypicalsFinal sampleTreatmentOlanzapineRisperidone
2000
Benchmarking Treatment of Schizophrenia
ROSENHECK R, DESAI R, STEINWACHS D, LEHMAN A. Benchmarking Treatment of Schizophrenia. The Journal Of Nervous And Mental Disease 2000, 188: 209-216. PMID: 10789997, DOI: 10.1097/00005053-200004000-00003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAmbulatory CareCase ManagementCommunity Mental Health ServicesDay Care, MedicalDelivery of Health CareHealth StatusHospitalizationHospitals, VeteransHumansMaleMiddle AgedOutcome Assessment, Health CarePatient Acceptance of Health CareQuality of Health CareSchizophreniaSocial AdjustmentSocial Work, PsychiatricUnited StatesUnited States Department of Veterans AffairsConceptsNon-VA patientsTreatment of schizophreniaVeterans AffairsVA outpatientsVA patientsPsychosocial servicesQuality of careCase management servicesCross-sectional surveyHealth care systemMale patientsClinical outcomesClinical statusHospital treatmentVA careTreatment recommendationsVA inpatientDay hospitalCrisis intervention servicesPatientsOutpatientsClinical diagnosisSimilar satisfactionIntervention servicesCare system